Here, Vidya shares a bit about what sparked her initial interest in metabolism research, and where she sees this rapidly evolving field going in the not-so-distant future.

Tell me about your research experience and what made you interested in metabolism research

My research journey began at the University of Verona, where I explored the clinically relevant question, ‘Why do some patients exhibit resistance to glucocorticoids?’, an investigation that led me to the fascinating crossroads of immunology and metabolism. In the early days, my work focused on understanding how immunomodulatory cytokines influence glucocorticoid metabolism, and whether these cytokines could be harnessed as adjuvant therapies to overcome glucocorticoid resistance.

This sparked my initial interest in metabolic regulation, and I built on this during my postdoctoral research at the National Council of Research in Naples. There, I investigated the metabolic pathways governing glycolipid synthesis and degradation. I was specifically interested in how an oncoprotein localized on the Golgi complex modulates levels of glycolipids and the toxic lipid ceramide—an imbalance that can disrupt lipid homeostasis and contribute to cancer progression.

During my academic career, I also explored the world of science communication as a freelance scientific and medical editor with Cactus Communications, a global science communications company.

Explain a bit about what you do at Abcam

I develop and execute product strategies that align with our long-term goals, identifying new opportunities, assessing what our customers need, and working closely with our R&D teams to bring new products from idea to launch. Having worked hands-on with many of our products, I’m able to put myself in the shoes of a researcher, which has been invaluable when designing solutions for our customers.

A big part of my day-to-day involves keeping a pulse on product performance to ensure we’re continuously providing researchers with the highest value and impact when it comes to our product solutions. I also collaborate closely with the Sales and Marketing teams – whether it’s delivering training, creating tools for customer engagement, or producing compelling content to showcase our offerings in the cardio-metabolic space.

Can you give an overview of the current landscape of metabolism research? What has the field traditionally been dominated by, and how have you seen this evolving?

Metabolism is fundamental to life. It governs how organisms generate, store, and use energy and influences virtually every cellular process. Historically, the field centered around mapping metabolites, enzyme functions, and pathway flux using foundational tools like isotopic labeling. But today, metabolism research looks quite different: it has evolved from classical biochemistry into a dynamic, disease-focused field, with emerging fields like cancer metabolism and immunometabolism revealing how metabolic rewiring fuels tumor growth and shapes immune responses.

The rising global burden of metabolic diseases, such as obesity, type 2 diabetes, and MASLD has propelled the field into the spotlight. Breakthrough discoveries in gut-brain communication and hormonal signaling are revolutionizing treatment strategies, and therapies such as Semaglutide (Wegovy) and Tirzepatide (Zepbound)  are achieving weight loss outcomes once thought possible only through bariatric surgery.

Powered by interdisciplinary tools, from single-cell ‘omics’ to AI-driven analytics, metabolism is no longer just a supporting player in biology. It’s emerging as a central axis of human health, offering insights that bridge molecular mechanisms with clinical impact, and reshaping how we understand, prevent, and treat disease.

What are the biggest challenges facing metabolism researchers today and how can we overcome them?

Metabolism research generates vast and complex datasets, largely driven by high-throughput ‘omics’ technologies. Unlike genes or proteins, metabolites – the small molecules that drive metabolism – are highly dynamic, tissue-specific, and sensitive to environmental changes. This lack of straightforward, one-to-one correlations makes it challenging to interpret data and draw conclusions. Researchers must rely on sophisticated computational tools and integrative approaches to connect these fragmented datasets, highlighting the need for standardized methods in sample preparation, data collection, and analysis.

Given the dynamic nature of metabolism, specificity in research tools is crucial. This is especially true when studying gut hormones, many of which exist in multiple forms: active, inactive, or rapidly degrading. To develop new therapies for conditions like obesity, researchers need highly specific antibodies and ELISA kits with minimal cross-reactivity. While current tools are useful, there's clear room for improving their precision and robustness to better reflect physiological complexity.

Another major challenge is the development of model systems that accurately represent human metabolism. For instance, in liver disease research, traditional models often fail to replicate the liver’s intricate structure and dynamic environment, leading to discrepancies between lab findings and clinical outcomes. Emerging platforms like liver organoids and organ-on-a-chip systems offer promise but still require refinement. Access to high-quality clinical samples remains limited, which adds another layer of complexity.

To overcome these hurdles, the field must invest in more robust research tools, standardized data integration strategies, and physiologically relevant models – critical steps toward deeper insights and more effective therapies in metabolic diseases.

What do you think the future holds for the field?

The future of metabolism research is incredibly exciting and rapidly evolving, marked by the emergence of new fields and cutting-edge technologies. Areas like microbiome–host interactions, nutrient sensing, and immunometabolism are gaining momentum, alongside a growing focus on compartment-specific metabolism and untargeted metabolomics. Advances in single-cell analysis and integrated multi-omics are providing deeper insights into how metabolic pathways are regulated in both health and disease, uncovering novel therapeutic targets and enabling more precise approaches to treatment.

What upcoming developments are you excited for? What promising treatment approaches are out there?

Thanks to decades of dedicated research, metabolism has already seen plenty of transformative breakthroughs – particularly in the development of multi-hormonal therapies. Dual and triple agonists targeting incretins have redefined how we treat obesity and type 2 diabetes. While incretins such as GLP-1 and GIP remain foundational to current obesity therapies, newer treatments such as CagriSema and Petrelintide, which target the hormone amylin (co-secreted with insulin and known to increase satiety), are showing strong promise in clinical trials.

While significant strides are being made in weight loss therapies, a crucial consideration is preserving muscle mass. Innovative strategies now include combining GLP-1 receptor agonists with resistance training or anabolic agents to counteract muscle loss. Therapies like bimagrumab – a monoclonal antibody that targets activin type II receptors – are also being explored for their ability to simultaneously promote muscle growth and reduce fat, offering a more balanced approach to obesity management.

Beyond metabolic diseases, GLP-1 receptor agonists are also being investigated for their potential to benefit cardiovascular conditions, Alzheimer’s disease, and liver disorders like MASH/MASLD, expanding their impact beyond traditional metabolic health.